X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to develop company's pipeline through preclinical studies, clinical trials and regulatory submissions, including VIP924, a first-in-class CXCR5-targeting ADC, being developed for the treatment of B-cell malignancies.
Lead Product(s): VIP924
Therapeutic Area: Oncology Product Name: VIP924
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $16.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 26, 2024
Details:
The net gross proceeds will be utilized to finance the clinical development of VIP236, which is currently undergoing early-stage clinical trials for the treatment of multiple neoplasms.
Lead Product(s): VIP236
Therapeutic Area: Oncology Product Name: VIP236
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering April 25, 2024
Details:
VIP152 (enitociclib) is a highly selective CDK9 inhibitor that prevents activation of RNA polymerase II, resulting in reduction of known oncogenes MYC and MCL1. It is currently in Phase 1/2 trials combination with venetoclax and prednisone for the treatment of Lymphoma.
Lead Product(s): Enitociclib,Venetoclax,Prednisone
Therapeutic Area: Oncology Product Name: VIP152
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2024
Details:
VIP943 is a novel ADC developed using Vincerx’s next-generation ADC technology designed to bind with CD123 and is being investigated in acute myeloid leukemia.
Lead Product(s): VIP943
Therapeutic Area: Oncology Product Name: VIP943
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
VIP943 is a novel ADC developed using Vincerx’s next-generation ADC technology designed to bind with CD123 and is being investigated in acute myeloid leukemia.
Lead Product(s): VIP943
Therapeutic Area: Oncology Product Name: VIP943
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2023
Details:
VIP236 is a small molecule drug conjugate with an optimized camptothecin payload having a significant activity in patient-derived and metastatic cancer models. It is being developed for treating multiple solid tumors.
Lead Product(s): VIP236
Therapeutic Area: Oncology Product Name: VIP236
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
VIP236 is a first-in-class SMDC with a tailored design to efficiently treat patients with cancer with aggressive and metastatic disease. VIP236 binds to activated αVβ3 integrin allowing specific homing to the tumor and is efficiently cleaved by neutrophil elastase (NE).
Lead Product(s): VIP236
Therapeutic Area: Oncology Product Name: VIP236
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
VIP943 is a next-generation ADC with a differentiated safety profile from currently approved ADCs. In vitro and in vivo studies using patient-derived AML cells show VIP943 has favorable monotherapy and combination efficacy including targeting of leukemic stem cells.
Lead Product(s): VIP943
Therapeutic Area: Oncology Product Name: VIP943
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation.
Lead Product(s): Enitociclib
Therapeutic Area: Oncology Product Name: VIP152
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
VIP152, a selective CDK9 inhibitor, induces complete regression of high-grade B-cell lymphoma (HGBL) models and depletion of short-lived oncogenic driver transcripts, MYC and MCL1, with a once weekly schedule.
Lead Product(s): Enitociclib
Therapeutic Area: Oncology Product Name: VIP152
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
